{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:18Z","timestamp":1789092438772,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["grant no. ZR2022QH127"],"award-info":[{"award-number":["grant no. ZR2022QH127"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Little is known regarding parameters predicting progressive disease (PD) for differentiated thyroid cancer (DTC) patients exhibiting biochemical incomplete response (BIR) after initial radioiodine (RAI) therapy. The aim of this study was to evaluate the long-term clinical outcomes of BIR patients and to establish the determinants of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials &amp;amp; methods<\/jats:title>\n                    <jats:p>172 DTC patients who were classified as BIR after initial RAI therapy between January 2010 to December 2023 in the Affiliated Hospital of Qingdao University were analyzed. All patients were received only one standardized RAI therapy. At the last follow-up, BIR patients were divided into the PD group and the non-progressive disease (NPD) group. PD was defined as the emergence of a new structural lesion or a \u226525% increase in thyroglobulin level. Univariate and multivariate Cox regression models were employed to identify independent risk factors associated with PD. Meanwhile, progression-free survival (PFS) for BIR patients were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a median follow-up of 48.6 months, 40.1% (69\/172) patients experienced PD. AJCC T stage (T1-T3a or T3b-T4; HR:2.073, 95%CI: 1.054-4.076, P = 0.035) and stimulated thyroglobulin (sTg, sTg&amp;lt; 50.0 ng\/mL or sTg\u2265 50.0 ng\/mL; HR: 3.056, 95%CI: 1.655-5.644, P&amp;lt;0.001) were verified to be the independent predictive factors of PD. The median PFS of BIR patients was 64.4 months and the 5-year PFS rate was 60.4%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sTg\u226550.0 ng\/mL and T3b-T4 stage are robust, clinically accessible markers identifying PD among BIR patients, warranting intensified surveillance and potentially earlier therapeutic reconsideration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1770829","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:22:53Z","timestamp":1769577773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term clinical outcomes of differentiated thyroid cancer patients with biochemical incomplete response after initial radioiodine therapy, a single-center, retrospective analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Congcong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Qingdao Women and Children\u2019s Hospital","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03844-x","article-title":"Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma","volume":"86","author":"Parvathareddy","year":"2024","journal-title":"Endocrine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02976-8","article-title":"Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study","volume":"76","author":"Wang","year":"2022","journal-title":"Endocrine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03989-9","article-title":"Diagnostic performance of 2-[18F]FDG PET\/CT in recurrent differentiated thyroid cancer and elevated antithyroglobulin antibodies: an updated systematic review and bivariate meta-analysis","volume":"87","author":"Albano","year":"2024","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: A review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1419141","article-title":"Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33690","article-title":"Thyroid cancer, recent advances in diagnosis and therapy","volume":"149","author":"Nabhan","year":"2021","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-025-00732-w","article-title":"From 2015 to 2025: how ATA guidelines reshape nuclear medicine practice in thyroid cancer","author":"Albano","year":"2025","journal-title":"Clin Trans Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid\u00ae"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031167","article-title":"A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer","volume":"89","author":"Sawka","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0178","article-title":"Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1080\/14796694.2024.2433407","article-title":"Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer","volume":"20","author":"Wang","year":"2024","journal-title":"Future Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02142-1","article-title":"Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response","volume":"67","author":"Ahn","year":"2020","journal-title":"Endocrine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04342.x","article-title":"Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy","volume":"77","author":"Vaisman","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021365","article-title":"Positive Predictive Value of Serum Thyroglobulin Levels, Measured during the First Year of Follow-Up after Thyroid Hormone Withdrawal, in Thyroid Cancer Patients","volume":"88","author":"Baudin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.3390\/cancers13215422","article-title":"Differentiated thyroid cancer with biochemical incomplete response: clinico-pathological characteristics and long term disease outcomes","volume":"13","author":"Steinschneider","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3322\/caac.21439","article-title":"Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"68","author":"Perrier","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0633","article-title":"Clinicopathological features predict outcomes in patients with radioiodine-refractory differentiated thyroid cancer treated with sorafenib: A real-world study","volume":"25","author":"Cheng","year":"2020","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12057","article-title":"Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET","volume":"78","author":"Marotta","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1217092","article-title":"Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2548161","article-title":"Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete response","volume":"21","author":"Wang","year":"2025","journal-title":"Future Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03187-5","article-title":"Incomplete response to therapy in intermediate- and high-risk thyroid cancer","volume":"78","author":"Alzahrani","year":"2022","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5911-6","article-title":"Disease progression in papillary thyroid cancer with biochemical incomplete response to initial therapy","volume":"24","author":"Zern","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0097-6","article-title":"Biochemical persistence in thyroid cancer: is there anything to worry about","volume":"46","author":"Fabi\u00e1n","year":"2013","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12020-018-1720-3","article-title":"Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer\u2014Where is the evidence","volume":"62","author":"Gray","year":"2018","journal-title":"Endocrine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26595","article-title":"Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer","volume":"64","author":"Albano","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0146","article-title":"2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma","volume":"11","author":"Lebbink","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-359","article-title":"Synergistic effects of histologic subtype, T-stage, and M-stage in the prognosis of differentiated thyroid cancer: a retrospective observational study","volume":"9","author":"Zhou","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4158\/EP-2019-0385","article-title":"Tumor size is an independent predictor of mortality risk in differentiated thyroid cancer patients with T4 disease","volume":"26","author":"Wang","year":"2020","journal-title":"Endocr Pract"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0051","article-title":"Does T stage affect prognosis in patients with stage Iv B differentiated thyroid cancer","volume":"25","author":"Li","year":"2019","journal-title":"Endocr Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1770829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:13:56Z","timestamp":1771924436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1770829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":33,"alternative-id":["10.3389\/fendo.2026.1770829"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1770829","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1770829"}}